Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II California cancer consortium trial

Primo N Lara, Paul H. Gumerlock, Philip Mack, Derick H Lau, Regina F Gandour-Edwards, Martin J. Edelman, Kathy S. Albain, Lisa Y. Law, Jeff Longmate, Paul Frankel, Gayatri P. Reddy, Valerie Israel, James H. Doroshow, David R Gandara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non - small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for platinum response status. Treatment consisted of gemcitabine 1000 mg/m2 given intravenously on days 1 and 8 of a 21-day cycle. The status of p53 in pretreatment tumor tissue was assessed by immunohistochemistry (IHC). Sixty-one patients who progressed or recurred following platinum-based therapy were enrolled, 26 platinum-sensitive and 35 platinum-refractory. A median of 4 treatment courses (range, 2-7 courses) was delivered. Of the 55 patients assessable for response, there was 1 confirmed complete response and 3 with a confirmed partial response for an overall response proportion of 7%. Twenty-one patients had stable disease while 28 progressed and 2 patients had an unconfirmed partial response. Three of the responders (2 confirmed, 1 unconfirmed) were platinum-refractory. Median progression-free survival (PFS) and overall survival for all patients were 4.1 months and 8.6 months, respectively. Median PFS and overall survival for the platinum-sensitive and platinum-refractory cohorts were 5.4 months versus 3.1 months, and 11.9 months versus 7.1 months, respectively. Toxicity was principally hematologic with grade 3/4 neutropenia in 21% and grade 4 platelets in 8%. There were no treatment-related deaths. Twenty-four of 33 patients (73%) had p53-positive tumors. Although no significant association between platinum sensitivity and p53 status was seen, patients with platinum-sensitive disease and negative p53 by IHC had a trend toward longer survival compared to those with platinum-refractory disease and/or p53 positivity (P = 0.06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)102-107
Number of pages6
JournalClinical Lung Cancer
Volume6
Issue number2
StatePublished - Sep 2004

Fingerprint

gemcitabine
Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Neoplasms
Disease-Free Survival
Survival
Immunohistochemistry

Keywords

  • Chemotherapy
  • Neutropenia
  • p53
  • Salvage therapy
  • Second-line treatment

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy : A phase II California cancer consortium trial. / Lara, Primo N; Gumerlock, Paul H.; Mack, Philip; Lau, Derick H; Gandour-Edwards, Regina F; Edelman, Martin J.; Albain, Kathy S.; Law, Lisa Y.; Longmate, Jeff; Frankel, Paul; Reddy, Gayatri P.; Israel, Valerie; Doroshow, James H.; Gandara, David R.

In: Clinical Lung Cancer, Vol. 6, No. 2, 09.2004, p. 102-107.

Research output: Contribution to journalArticle

Lara, Primo N ; Gumerlock, Paul H. ; Mack, Philip ; Lau, Derick H ; Gandour-Edwards, Regina F ; Edelman, Martin J. ; Albain, Kathy S. ; Law, Lisa Y. ; Longmate, Jeff ; Frankel, Paul ; Reddy, Gayatri P. ; Israel, Valerie ; Doroshow, James H. ; Gandara, David R. / Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy : A phase II California cancer consortium trial. In: Clinical Lung Cancer. 2004 ; Vol. 6, No. 2. pp. 102-107.
@article{ac21409658434cdda029da4f185b844c,
title = "Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II California cancer consortium trial",
abstract = "A phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non - small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for platinum response status. Treatment consisted of gemcitabine 1000 mg/m2 given intravenously on days 1 and 8 of a 21-day cycle. The status of p53 in pretreatment tumor tissue was assessed by immunohistochemistry (IHC). Sixty-one patients who progressed or recurred following platinum-based therapy were enrolled, 26 platinum-sensitive and 35 platinum-refractory. A median of 4 treatment courses (range, 2-7 courses) was delivered. Of the 55 patients assessable for response, there was 1 confirmed complete response and 3 with a confirmed partial response for an overall response proportion of 7{\%}. Twenty-one patients had stable disease while 28 progressed and 2 patients had an unconfirmed partial response. Three of the responders (2 confirmed, 1 unconfirmed) were platinum-refractory. Median progression-free survival (PFS) and overall survival for all patients were 4.1 months and 8.6 months, respectively. Median PFS and overall survival for the platinum-sensitive and platinum-refractory cohorts were 5.4 months versus 3.1 months, and 11.9 months versus 7.1 months, respectively. Toxicity was principally hematologic with grade 3/4 neutropenia in 21{\%} and grade 4 platelets in 8{\%}. There were no treatment-related deaths. Twenty-four of 33 patients (73{\%}) had p53-positive tumors. Although no significant association between platinum sensitivity and p53 status was seen, patients with platinum-sensitive disease and negative p53 by IHC had a trend toward longer survival compared to those with platinum-refractory disease and/or p53 positivity (P = 0.06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC.",
keywords = "Chemotherapy, Neutropenia, p53, Salvage therapy, Second-line treatment",
author = "Lara, {Primo N} and Gumerlock, {Paul H.} and Philip Mack and Lau, {Derick H} and Gandour-Edwards, {Regina F} and Edelman, {Martin J.} and Albain, {Kathy S.} and Law, {Lisa Y.} and Jeff Longmate and Paul Frankel and Reddy, {Gayatri P.} and Valerie Israel and Doroshow, {James H.} and Gandara, {David R}",
year = "2004",
month = "9",
language = "English (US)",
volume = "6",
pages = "102--107",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

T2 - A phase II California cancer consortium trial

AU - Lara, Primo N

AU - Gumerlock, Paul H.

AU - Mack, Philip

AU - Lau, Derick H

AU - Gandour-Edwards, Regina F

AU - Edelman, Martin J.

AU - Albain, Kathy S.

AU - Law, Lisa Y.

AU - Longmate, Jeff

AU - Frankel, Paul

AU - Reddy, Gayatri P.

AU - Israel, Valerie

AU - Doroshow, James H.

AU - Gandara, David R

PY - 2004/9

Y1 - 2004/9

N2 - A phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non - small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for platinum response status. Treatment consisted of gemcitabine 1000 mg/m2 given intravenously on days 1 and 8 of a 21-day cycle. The status of p53 in pretreatment tumor tissue was assessed by immunohistochemistry (IHC). Sixty-one patients who progressed or recurred following platinum-based therapy were enrolled, 26 platinum-sensitive and 35 platinum-refractory. A median of 4 treatment courses (range, 2-7 courses) was delivered. Of the 55 patients assessable for response, there was 1 confirmed complete response and 3 with a confirmed partial response for an overall response proportion of 7%. Twenty-one patients had stable disease while 28 progressed and 2 patients had an unconfirmed partial response. Three of the responders (2 confirmed, 1 unconfirmed) were platinum-refractory. Median progression-free survival (PFS) and overall survival for all patients were 4.1 months and 8.6 months, respectively. Median PFS and overall survival for the platinum-sensitive and platinum-refractory cohorts were 5.4 months versus 3.1 months, and 11.9 months versus 7.1 months, respectively. Toxicity was principally hematologic with grade 3/4 neutropenia in 21% and grade 4 platelets in 8%. There were no treatment-related deaths. Twenty-four of 33 patients (73%) had p53-positive tumors. Although no significant association between platinum sensitivity and p53 status was seen, patients with platinum-sensitive disease and negative p53 by IHC had a trend toward longer survival compared to those with platinum-refractory disease and/or p53 positivity (P = 0.06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC.

AB - A phase II trial was designed to evaluate the efficacy and toxicity of gemcitabine in patients with non - small-cell lung cancer (NSCLC) previously treated with platinum-containing regimens and prospectively categorized for platinum response status. Treatment consisted of gemcitabine 1000 mg/m2 given intravenously on days 1 and 8 of a 21-day cycle. The status of p53 in pretreatment tumor tissue was assessed by immunohistochemistry (IHC). Sixty-one patients who progressed or recurred following platinum-based therapy were enrolled, 26 platinum-sensitive and 35 platinum-refractory. A median of 4 treatment courses (range, 2-7 courses) was delivered. Of the 55 patients assessable for response, there was 1 confirmed complete response and 3 with a confirmed partial response for an overall response proportion of 7%. Twenty-one patients had stable disease while 28 progressed and 2 patients had an unconfirmed partial response. Three of the responders (2 confirmed, 1 unconfirmed) were platinum-refractory. Median progression-free survival (PFS) and overall survival for all patients were 4.1 months and 8.6 months, respectively. Median PFS and overall survival for the platinum-sensitive and platinum-refractory cohorts were 5.4 months versus 3.1 months, and 11.9 months versus 7.1 months, respectively. Toxicity was principally hematologic with grade 3/4 neutropenia in 21% and grade 4 platelets in 8%. There were no treatment-related deaths. Twenty-four of 33 patients (73%) had p53-positive tumors. Although no significant association between platinum sensitivity and p53 status was seen, patients with platinum-sensitive disease and negative p53 by IHC had a trend toward longer survival compared to those with platinum-refractory disease and/or p53 positivity (P = 0.06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC.

KW - Chemotherapy

KW - Neutropenia

KW - p53

KW - Salvage therapy

KW - Second-line treatment

UR - http://www.scopus.com/inward/record.url?scp=7444257975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444257975&partnerID=8YFLogxK

M3 - Article

C2 - 15476595

AN - SCOPUS:7444257975

VL - 6

SP - 102

EP - 107

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -